# Hepatitis B Birth Dose for Newborns

> **NCT04870021** · PHASE4 · COMPLETED · sponsor: **Quaid-e-Azam University** · enrollment: 218 (actual)

## Conditions studied

- Hepatitis B
- Immunization; Infection

## Interventions

- **BIOLOGICAL:** recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm),
- **BEHAVIORAL:** Short text messages and calls to parents for compliance to routine immunization schedule

## Key facts

- **NCT ID:** NCT04870021
- **Lead sponsor:** Quaid-e-Azam University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-15
- **Primary completion:** 2015-11-30
- **Final completion:** 2016-06-30
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2021-05-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04870021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04870021, "Hepatitis B Birth Dose for Newborns". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04870021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*